Adamas

Driven to Address Chronic CNS Disorders

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), based in Emeryville, California, is driven to improve the lives of those affected by chronic disorders of the central nervous system.  The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products.  Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment.  The company is also evaluating ADS-4101, an extended-release version of an FDA-approved single-agent compound for the treatment of epilepsy.  The company's portfolio includes Namzaric™ and Namenda XR®, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc.  Forest is responsible for marketing both products in the United States under an exclusive license from Adamas.  To learn more, visit www.adamaspharma.com.

 

Facts & Stats

  • Adamas went public in April 2014, trading on the Nasdaq stock market under the ticker, ‘ADMS’.
  • Adamas’ diversified business model provides the company with the flexibility to develop products on its own or in partnership with others.
  • If approved, Adamas plans to commercialize ADS-5102 and potentially other wholly-owned product candidates through a targeted CNS commercial organization.